Traws Pharma (TRAW) COO gets 22,435 options at $3.01; 2035 exp

Traws Pharma (TRAW) reported an insider equity award.

Rhea-AI Filing Summary

Traws Pharma (TRAW) reported an insider equity award. Chief Operating Officer and Director Nikolay Savchuk was granted a stock option for 22,435 shares at an exercise price of $3.01 on 10/12/2025.

The option vests 100% on 10/12/2026 and expires on 10/12/2035. The filing lists the holdings as Direct (D). This is a routine compensatory grant disclosed on Form 4.

Insider Trade Summary

Grant/Award: 22,435 shares

Grant/Award 1 txn

Insider Savchuk Nikolay

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to purchase)	22,435	$0.00	$0.00

Holdings After Transaction: Stock Option (right to purchase) — 22,435 contracts (Direct)

Footnotes (1)

1. F1. The options vest 100% on the first anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Traws Pharma (TRAW) disclose in this Form 4?

A stock option grant to COO and Director Nikolay Savchuk for 22,435 shares at an exercise price of $3.01 on 10/12/2025.

What are the vesting terms of the TRAW option grant?

The options vest 100% on the first anniversary of the grant date, 10/12/2026.

When do the reported TRAW options expire?

The options expire on 10/12/2035.

How many shares underlie the TRAW option grant?

The option covers 22,435 shares of common stock.

What is the ownership form reported for the TRAW options?

The ownership form is listed as Direct (D).

Who is the reporting person in the TRAW Form 4?

The reporting person is Nikolay Savchuk, Chief Operating Officer and Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savchuk Nikolay

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$3.01	10/12/2025		A		22,435		10/12/2026(1)	10/12/2035	Common Stock	22,435	$0	22,435	D

Explanation of Responses:

1. The options vest 100% on the first anniversary of the grant date.

	/s/ Nikolay Savchuk	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.